Acquisition History / AbbVie Inc. / Apogee Therapeutics, Inc.
AbbVie Inc. Acquires Apogee Therapeutics, Inc.
Announced August 10, 2026 — $10.90B
What happened
AbbVie agreed on August 10, 2026 to acquire all outstanding shares of Apogee Therapeutics for $135.11 per share in cash, representing a total equity value of approximately $10.9B.
- Acquirer
- AbbVie Inc.
- Target
- Apogee Therapeutics, Inc.
- Announced
- August 10, 2026
- Price
- $10.90B
- Industry
- Immunology biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did AbbVie Inc. acquire Apogee Therapeutics, Inc.?
AbbVie Inc. acquired Apogee Therapeutics, Inc. on August 10, 2026. This was AbbVie Inc.'s 1st publicly tracked acquisition out of 1 we have on record.
How much did AbbVie Inc. pay for Apogee Therapeutics, Inc.?
AbbVie Inc. paid $10.90B for Apogee Therapeutics, Inc..
What does Apogee Therapeutics, Inc. do?
AbbVie agreed on August 10, 2026 to acquire all outstanding shares of Apogee Therapeutics for $135.11 per share in cash, representing a total equity value of approximately $10.9B.
What other Immunology biotechnology companies has AbbVie Inc. acquired?
Apogee Therapeutics, Inc. is AbbVie Inc.'s only publicly tracked acquisition in Immunology biotechnology so far.